Published in final edited form as:

J Med Chem. 2009 January 22; 52(2): 238–240. doi:10.1021/jm8013579.

Total Synthesis and Biological Evaluation of Tubulysin U, Tubulysin V, and their Analogs

Ranganathan Balasubramanian[†], Bhooma Raghavan[†], Adrian Begaye[‡], Dan L. Sackett[‡], and Robert A. Fecik^{†,*}

[†]Department of Medicinal Chemistry, 308 Harvard Street S.E., 8-101 Weaver–Densford Hall, University of Minnesota, Minneapolis, Minnesota 55455-0353

[‡]Laboratory of Integrative and Medical Biophysics, National Institute of Child Health Human Development, National Institutes of Health, 9 Memorial Drive, Building 9, Room 1E129, Bethesda, Maryland 20892-0924

Abstract

A stereoselective total synthesis of the cytotoxic natural products tubulysin U, tubulysin V, and its unnatural epimer epi-tubulysin V, is reported. A series of simplified analogs containing *N,N*-dimethyl-D-alanine as a replacement for the N-terminal *N*-Me-pipecolinic acid residue of the tubulysins is also disclosed. Biological evaluation of these natural products and analogs provided key information with regard to structural and stereochemical requirements for anti-proliferative activity and tubulin polymerization inhibition.

The tubulysins (**1–7**, Chart 1) are a group of extremely potent tubulin polymerization inhibitors that rapidly disintegrate the cytoskeleton of dividing cells and induce apoptosis.¹ Tubulysins are produced in very limited quantities by fermentation of the myxobacteria *Angiococcus disciformis* and *Archangium gephyra*.^{1a,b} Biosynthesis of tubulysins is accomplished by an unusual mixed nonribosomal peptide synthetase–polyketide synthase (NRPS–PKS) system.² This has led to extensive investigations into their total synthesis and the synthesis of novel analogs.^{3–6} The most active natural product known so far in this family is tubulysin D (**2**), which retains its anticancer activity against the multidrug resistant P-glycoprotein-expressing human KB-V1 cervix carcinoma cell line (IC₅₀ = 0.31 nM).^{1b} This activity profile makes the tubulysins exciting leads for the treatment of multidrug resistant cancers.

Structurally, tubulysins are tetrapeptides comprised of *N*-methylpipecolinic acid (Mep) at the N-terminus, isoleucine (Ile, the only proteinogenic amino acid) as the second residue, the unique thiazole-containing tubuvaline (Tuv) as the third residue, and two possible γ -amino acids at the C-terminus: tubutyrosine (Tut) or tubuphenylalanine (Tup). An acetylated alcohol and an *N,O*-acetal in tubuvaline are found in most members of this natural product family. Tubulysins U–X (**3–6**), and Z (**7**) are the only natural tubulysins in which one or

*To whom correspondence should be address. Phone: 612-626-6523. Fax: 612-624-0139, fecik001@umn.edu.

Supporting Information **Available:** Experimental procedures, spectroscopic data, and copies of NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

both of these functional groups are not present. Although these are relatively simple molecules to envision a total synthesis of, there are a number of challenging synthetic issues as summarized in a recent review³ 1) the installation of the extremely sensitive *N,O*-acetal, 2) the synthesis of the complex thiazole-containing Tuv, and 3) the assembly of the tetrapeptide, as a consequence of the sterically congested Tuv region.

The total synthesis of tubulysins D,⁴ U and V,⁵ and numerous analogs⁶ has allowed for determination of structure–activity relationship (SAR) studies for these natural products. In a report by Wipf and co-workers, it was established that the Mep residue at the N-terminus of the tubulysins could be replaced with the acyclic amino acid *N*-methylsarcosine.^{6b} This observation was corroborated by Ellman and co-workers who reported that incorporation of *N*-methylsarcosine in the place of Mep provided a tubulysin analog with equal antiproliferative activity to tubulysin D.^{6c} The latter group extended the SAR of this family of peptides by stating that a basic tertiary amine was required at the Mep residue for activity, a finding that was confirmed by our research group.^{6d,e}

We have recently reported the synthesis and initial biological activity of a series of simplified tubulysin analogs lacking the *N,O*-acetal and having the acetate group of Tuv replaced with a ketone.^{6d,e} Systematic modifications of the Mep residue (*N*-desmethyl, stereochemistry, and ring size) and Tup residue (desmethyl and dimethyl substituents in place of the stereogenic α -methyl group) have enabled us to establish the minimal structural requirements for cytotoxicity. Our simplified analogs having a ketone in the Tuv residue are perfect precursors to tubulysins U and V (**3** and **4**). Usually, this latter series of tubulysins is less active, but tubulysins U and V were reported to have bioactivity similar to paclitaxel and the epothilones.^{1b} Herein, we report the total synthesis and biological activity of tubulysins U and V, and a series of simplified analogs in which the Mep residue has been replaced with *N,N*-dimethyl-D-alanine. This data extends our SAR studies of these important natural products.

Before attempting the reduction of a full-length tetrapeptide precursor to tubulysin V, we performed a non-stereoselective NaBH₄ reduction on dipeptide **8**^{6d} (Scheme 1). This reaction was used as a model to assess the selectivity of reduction and to establish the stereochemistry of the two alcohol products. A mixture of alcohols **9** and **10** were obtained with 1:3 selectivity, and were readily separable by chromatography. The stereochemistry of the major product **10** was determined by modified Mosher analysis⁷ of the ¹H NMR spectrum of MTPA esters **11** and **12**, formed by reaction of alcohol **10** with (*R*)- and (*S*)-MTPA-Cl, respectively.

We next sought to examine the reduction of tetrapeptide **13** to give a protected precursor of tubulysin V. Reduction of tetrapeptide **13** with NaBH₄ also afforded a mixture of the two diastereomeric alcohol products **14** with little selectivity (2.4:1, Scheme 2). Each diastereomer was isolated and individually characterized. The stereochemistry of each diastereomer was later determined by spectral comparison to the immediate precursor to tubulysin V. CBS reduction⁸ of tetrapeptide **13** gave intractable mixtures, so we then attempted the reduction of a tripeptide intermediate.

Tripeptide intermediate **15** was found to be optimal for achieving stereoselective reduction of the Tuv ketone. Reduction of tripeptide **15** with NaBH₄ and the Luche reagent⁹ failed to produce any significant diastereoselectivity. We were gratified to find that treatment of tripeptide **15** with the (*S*)-CBS or (*R*)-CBS reagent in the presence of BH₃•DMS almost exclusively afforded the reduced tripeptides **16** and **17**, respectively (Schemes 3 and 4). The stereochemical outcome of these reactions was supported by the following: 1) the ¹H NMR spectrum of **4** matched that of tubulysin V as previously reported,^{5a} and 2) the findings of Zanda and co-workers who reported that the (*S*)-CBS reagent with BH₃•DMS reacted nearly exclusively from the *si* face of the ketone of a racemic Tuv intermediate to give the alcohol products possessing the natural configuration as established by X-ray crystallography.^{5a} The ¹H NMR spectrum of the immediate tetrapeptide benzyl ester precursor of tubulysin V was identical to the minor diastereomer **14**, enabling us to assign the stereochemistry of the purified diastereomers **14**.

The total synthesis of tubulysin V (**4**) was completed by amino group deprotection of reduced tripeptide **16**, followed by coupling with *N*-Me-D-Pip and saponification of the benzyl ester (Scheme 3). Interestingly, purification of tubulysin V by reverse-phase HPLC under the conditions reported by Dömling and co-workers^{5b} using MeOH as the mobile phase resulted in isolation of the methyl ester to a significant extent (38%). Using acetonitrile as the mobile phase smoothly afforded the natural product in an analytically pure form. Acetylation of the secondary hydroxyl group of Tuv contained in tubulysin V (**4**) under standard conditions afforded a second natural product, tubulysin U (**3**, Scheme 3). Epi-tubulysin V (**18**) was synthesized and isolated in an identical fashion starting from reduced tripeptide **17** (Scheme 4).

A small series of simplified analogs in which the N-terminal residue of the tubulysins (Mep) was replaced with the acyclic *N,N*-dimethyl-D-alanine was synthesized to extend our previous findings and those of Wipf and Ellman. Synthesis of these analogs follows our published route for the synthesis of other series of simplified analogs.^{6d,e} Tripeptides **15**, **19**, and **20** were deprotected, coupled with *N,N*-dimethyl-D-Ala, and saponified to afford tetrapeptides **21–23** (Scheme 5).

Tubulysins U, V, and analogs **18** and **21–23** were evaluated for anti-proliferative activity in 1A9 ovarian cancer cells and MCF-7 breast cancer cells, and for *in vitro* inhibition of tubulin polymerization (Table 1).^{6d,e,8} The hemiasterlin analog HTI-286 (SPA110) was used as a positive control in all assays.

Tubulysin V is about 30–45 fold more active than epi-tubulysin V in the antiproliferative assays, suggesting that the absolute configuration of the secondary alcohol in tubulysin is important for activity. Acetylation of this alcohol to produce tubulysin U caused a dramatic improvement in potency by three orders of magnitude, possibly due its increased lipophilicity and potential to cross cell membranes more effectively. The simplified analogs **21–23** which contain an acyclic Mep variant vary widely in their antiproliferative activity. Compound **22** has sub-micromolar activity similar to tubulysin V, whereas compound **21** was not active at the highest concentration tested (50 μM). Analog **23** has intermediate activity that is less than epi-tubulysin V. The antiproliferative assay results for analogs **21–**

23 differ from the trends observed for other series, where the incorporation of dimethyltubophenylalanine increased activity.^{6d,e}

Tubulysins U, V, and epi-tubulysin V approach the potency of HTI-286 in the *in vitro* tubulin polymerization inhibition assay. Interestingly, amongst all compounds evaluated in Table 1, inhibition of tubulin polymerization does not correlate with antiproliferative activity. The reasons for this are not clear at this time, and are the subject of ongoing investigations.

We report here a stereoselective total synthesis of tubulysins U and V, epi-tubulysin V, and a series of simplified analogs. Biological evaluation of the natural products established the importance of the acetate and hydroxyl groups in the Tuv residue. The extremely potent antiproliferative activity of tubulysin U indicates that a tertiary amide between the Ile and Tuv residues, exemplified by the *N,O*-acetal found in tubulysins A and D, is not required. Data obtained from the simplified analogs **21–23** suggest that a cyclic constraint at the N-terminal Mep residue is not a requirement for activity. The results presented here suggest ways to improve the anti-proliferative activity of simplified tubulysin analogs. These and other modifications to the tubulysin scaffold, and further biological evaluation of select analogs will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was generously supported by the American Cancer Society, Grant RSG-05-105-01-CDD (to R.A.F.), and was supported in part by intramural funds from the National Institute of Child Health and Human Development, NIH. Funding for NMR instrumentation in the Department of Biochemistry, Molecular Biology, and Biophysics was provided by the University of Minnesota Medical School, NSF (BIR-961577), and the Minnesota Medical Foundation.

References

1. (a) Sasse F, Steinmetz H, Heil J, Höfle G, Reichenbach H. Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. *J Antibiot.* 2000; 53:879–885. [PubMed: 11099220] (b) Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, Höfle G. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins – powerful inhibitors of tubulinpolymerization from myxobacteria. *Angew Chem Int Ed.* 2004; 43:4888–4892. (c) Khalil MW, Sasse F, Lünsdorf H, Elnakady YA, Reichenbach H. Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. *ChemBioChem.* 2006; 7:678–683. [PubMed: 16491500] (d) Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Dömling A, Agarwal S. Biological evaluation of tubulysin A: A potential anticancer and antiangiogenic natural product. *Biochem J.* 2006; 396:235–242. [PubMed: 16489930]
2. Sandmann A, Sasse F, Müller R. Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. *Chem Biol.* 2004; 11:1071–1079. [PubMed: 15324808]
3. Neri D, Fossati G, Zanda M. Efforts toward the total synthesis of tubulysins: New hopes for a more effective targeted drug delivery to tumors. *ChemMedChem.* 2006; 1:175–180. [PubMed: 16892348]
4. Peltier HM, McMahon JP, Patterson AW, Ellman JA. The total synthesis of tubulysin D. *J Am Chem Soc.* 2006; 128:16018–16019. [PubMed: 17165738]

5. a Sani M, Fossati G, Huguenot F, Zanda M. Total synthesis of tubulysins U and V. *Angew Chem Int Ed.* 2007; 46:3526–3529. (b) Dömling A, Beck B, Eichelberger U, Sakamuri S, Menon S, Chen QZ, Lu Y, Wessjohann LA. Total synthesis of tubulysin U and V. *Angew Chem Int Ed.* 2006; 45:7235–7239. (c) Dömling A, Beck B, Eichelberger U, Sakamuri S, Menon S, Chen QZ, Lu Y, Wessjohann LA. Total synthesis of tubulysin U and V. *Angew Chem Int Ed.* 2007; 46:2347–2348. Corrigendum.
6. (a) Wipf P, Wang Z. Total synthesis of N^{14} -desacetoxytubulysin H. *Org Lett.* 2007; 9:1605–1607. [PubMed: 17367155] (b) Wang Z, McPherson PA, Raccor BS, Balachandran R, Zhu G, Day BW, Vogt A, Wipf P. Structure–activity and high-content imaging analyses of novel tubulysins. *Chem Biol Drug Des.* 2007; 70:75–86. [PubMed: 17683369] (c) Patterson AW, Peltier HM, Sasse F, Ellman JA. Design, synthesis, and biological properties of highly potent tubulysin D analogues. *Chem Eur J.* 2007; 13:9534–9541. [PubMed: 17828721] (d) Raghavan B, Balasubramanian R, Steele JC, Sackett DL, Fecik RA. Cytotoxic simplified tubulysin analogues. *J Med Chem.* 2008; 51:1530–1533. [PubMed: 18314944] (e) Balasubramanian R, Raghavan B, Steele JC, Sackett DL, Fecik RA. Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives. *Bioorg Med Chem Lett.* 2008; 18:2996–2999. [PubMed: 18411048] (f) Friestad GK, Marié JC, Deveau AM. Stereoselective Mn-Mediated Coupling of Functionalized Iodides and Hydrazones: A Synthetic Entry to the Tubulysin γ -Amino Acids. *Org Lett.* 2004; 6:3249–3252. [PubMed: 15355024]
7. Ohtani I, Kusumi T, Kashman Y, Kakisawa H. High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids. *J Am Chem Soc.* 1991; 113:4092–4096.
8. Corey EJ, Helal CJ. Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: A new paradigm for enantioselective catalysis and a powerful synthetic method. *Angew Chem Int Ed Engl.* 1998; 37:1986–2012.
9. Gemal A, Luche JL. Lanthanoids in organic synthesis. 6. Reduction of α -enones by sodium borohydride in the presence of lanthanoid chlorides: Synthetic and mechanistic aspects. *J Am Chem Soc.* 1981; 103:5454–5459.
10. Hamel E. Evaluation of antimetabolic agents by quantitative comparison of their effects on the polymerization of purified tubulin. *Cell Biochem Biophys.* 2003; 38:1–21. [PubMed: 12663938]

Abbreviations

Ala	alanine
CBS	Corey–Bakshi–Shibata
Ile	isoleucine
Mep	<i>N</i> -methylpipecolinic acid
MTPA	α -methoxy- α -trifluoromethylphenylacetic acid
NRPS	nonribosomal peptide synthetase
PKS	polyketide synthase
Pip	pipecolinic acid
SAR	structure–activity relationship
Tup	tubuphenylalanine
Tut	tubutyrosine
Tuv	tubuvaline

Scheme 1. Non-selective Reduction of Dipeptide 8

Scheme 2. Non-stereoselective Reduction of Tetrapeptide 13

Scheme 4. Synthesis of Epi-tubulysin V

Scheme 5. Synthesis of Simplified Tubulysin Analogs 21–23

Mep	Ile	Tuv	Tup or Tut
Tubulysin A (1), $R^1 = \text{OH}$, $R^2 = \text{Ac}$, $R^3 = \text{CH}_2\text{OC(O)CH}_2\text{CHMe}_2$			
Tubulysin D (2), $R^1 = \text{H}$, $R^2 = \text{Ac}$, $R^3 = \text{CH}_2\text{OC(O)CH}_2\text{CHMe}_2$			
Tubulysin U (3), $R^1 = \text{H}$, $R^2 = \text{Ac}$, $R^3 = \text{H}$			
Tubulysin V (4), $R^1 = \text{H}$, $R^2 = \text{H}$, $R^3 = \text{H}$			
Tubulysin W (5), $R^1 = \text{OH}$, $R^2 = \text{H}$, $R^3 = \text{CH}_2\text{OC(O)CH}_2\text{CH}_2\text{Me}$			
Tubulysin X (6), $R^1 = \text{OH}$, $R^2 = \text{Ac}$, $R^3 = \text{H}$			
Tubulysin Z (7), $R^1 = \text{OH}$, $R^2 = \text{H}$, $R^3 = \text{H}$			

Chart 1.

Table 1
Biological Activity of Tubulysins U, V, and Analogs

Compound ^a	Inhibition of proliferation (IC ₅₀ , μM) ^b		Tubulin inhibition (IC ₅₀ , μM) ^c
	1A9	MCF-7	
3 (tubulysin U)	0.00065	0.0004	1.9
4 (tubulysin V)	0.12	0.24	1.1
18 (epi-tubulysin V)	5.1	8.1	1.3
21 (FT-040)	>50	ND ^d	3.6
22 (FT-039)	0.3	0.17	12.5
23 (FT-038)	14.2	12.2	8.5
HTI-286 (SPA110)	0.0002	0.00015	0.7

^a Compounds were isolated and tested as their HCl salts.

^b Values are means of two independent IC₅₀ determinations with a maximum drug concentration of 50 mM in DMSO.

^c In vitro inhibition of tubulin polymerization.

^d ND, not determined.